Search Result

Isoforms Recommended:	CXCR1

Results for "

Cxcr1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CXCR (25) Apoptosis (1) Arrestin (1) IFNAR (1) Interleukin Related (2) mRNA (1) Reference Standards (5) Small Interfering RNA (siRNA) (3) TNF Receptor (1)
By Research Areas:	Cancer (11) Endocrinology (14) Infection (2) Inflammation/Immunology (22)
Oligonucleotides:	Chemokine & Receptors (1) Rat Pre-designed siRNA Sets (1) mRNA (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Oligonucleotides

Targets Recommended: CXCR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15251

Reparixin Maximum Cited Publications 62 Publications Verification Repertaxin; DF 1681Y	CXCR	Inflammation/Immunology Endocrinology Cancer
Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors *CXCR1* and *CXCR2* activation with IC₅₀s of 1 and 100 nM, respectively.

HY-10198

Navarixin 30+ Cited Publications SCH 527123; MK-7123	CXCR	Inflammation/Immunology Endocrinology Cancer
Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both *CXCR1* and *CXCR2, with K_d* values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly ^[1] .

HY-119339

SX-682 5+ Cited Publications	CXCR	Inflammation/Immunology Endocrinology Cancer
SX-682 is an orally bioavailable, potent allosteric inhibitor of *CXCR1* and *CXCR2*. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity ^[1].

HY-15252

Reparixin L-lysine salt Maximum Cited Publications 62 Publications Verification Repertaxin L-lysine salt	CXCR	Inflammation/Immunology Endocrinology Cancer
Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.

HY-19519A

Ladarixin sodium 1 Publications Verification DF 2156A	CXCR	Infection Inflammation/Immunology Cancer
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual *CXCR1* and *CXCR2* antagonist. Ladarixin sodium can be used for the research of COPD and asthma ^[1].

HY-19519

Ladarixin 1 Publications Verification DF 2156A free base	CXCR	Inflammation/Immunology Cancer
Ladarixin (DF 2156A free base) is an orally active, allosteric non-competitive and dual *CXCR1* and *CXCR2* antagonist. Ladarixin can be used for the research of COPD and asthma ^[1].

HY-165428

SCH-900875	CXCR Arrestin	Inflammation/Immunology
SCH-900875 is an orally active, brain-penetrant and selective CXCR3 receptor inhibitor, which also shows high selectivity over *CXCR1* and CXCR2 receptors. SCH-900875 binds to CXCR3, blocking the binding of ligands CXCL9, CXCL10, and CXCL11, inhibiting downstream G protein and β-arrestin signaling pathways to suppress inflammatory cell migration. SCH-900875 is promising for research of autoimmune diseases (rheumatoid arthritis, multiple sclerosis) and inflammatory disorders (psoriasis, inflammatory bowel disease) ^[1] .

HY-120878

CXCR2-IN-2 1 Publications Verification	CXCR	Inflammation/Immunology
CXCR2-IN-2 is a selective, brain penetrant, and orally bioavailable *CXCR2* antagonist (IC₅₀=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC₅₀ of 0.04 μM ^[1].

HY-10011

SCH 563705 4 Publications Verification	CXCR	Inflammation/Immunology Endocrinology
SCH 563705 is a potent and orally available *CXCR2* and *CXCR1* antagonist, with IC₅₀s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively.

HY-16981

SB-332235	CXCR	Inflammation/Immunology
SB-332235 is a potent, orally active nonpeptide *CXCR2* antagonist, with an IC₅₀ of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells ^[1] .

HY-174728

*Human CXCR1* mRNA**	mRNA	Inflammation/Immunology
Human CXCR1 mRNA encodes the human C-X-C motif chemokine receptor 1 (CXCR1) protein, a member of the G-protein-coupled receptor family. CXCR1 is a receptor for interleukin 8 (IL8). It binds to IL8 with high affinity, and transduces the signal through a G-protein activated second messenger system.

HY-15251A

(Rac)-Reparixin (Rac)-Repertaxin; (Rac)-DF 1681Y	CXCR	Inflammation/Immunology Endocrinology Cancer
(Rac)-Reparixin is the isomer of Reparixin (HY-15251), and can be used as an experimental control. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors *CXCR1* and *CXCR2* activation with IC₅₀s of 1 and 100 nM, respectively.

HY-163475

*CXCL-CXCR1/2-IN-1* 1 Publications Verification	CXCR	Cancer
CXCL-CXCR1/2-IN-1 is an orally active ELR ⁺CXCL-CXCR1/2 pathway inhibitor with an EC₅₀ of 42.7 nM for CXCR2 ^[1]. CXCL-CXCR1/2-IN-1 shows anticancer and antiangiogenic effects ^[1].

HY-P4846

Ac-Pro-Gly-Pro-OH 2 Publications Verification	CXCR Apoptosis IFNAR TNF Receptor Interleukin Related	Infection Inflammation/Immunology
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a *CXCR2* agonist . Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer ^[1] .

HY-RS03399

Cxcr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
Cxcr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr1 Rat Pre-designed siRNA Set A Cxcr1 Rat Pre-designed siRNA Set A

HY-RS03398

Cxcr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
Cxcr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cxcr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cxcr1 Mouse Pre-designed siRNA Set A Cxcr1 Mouse Pre-designed siRNA Set A

HY-RS03397

CXCR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) CXCR	Others
CXCR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CXCR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CXCR1 Human Pre-designed siRNA Set A CXCR1 Human Pre-designed siRNA Set A

HY-15251R

Reparixin (Standard) Repertaxin (Standard); DF 1681Y (Standard)	CXCR Reference Standards	Inflammation/Immunology Endocrinology Cancer
Reparixin (Standard) is the analytical standard of Reparixin. This product is intended for research and analytical applications. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.

HY-10011A

(S)-SCH 563705	CXCR	Inflammation/Immunology Endocrinology
(S)-SCH 563705 is a S-enantiomer of SCH 563705. SCH 563705 (compound 16) is a potent and orally available *CXCR2* and *CXCR1* antagonist, with IC₅₀s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively ^[1] .

HY-10011B

(Rac)-SCH 563705	CXCR	Inflammation/Immunology Endocrinology
(Rac)-SCH 563705 is a racemic mixture of SCH 563705 (HY-10011). SCH 563705 (compound 16) is a potent and orally active *CXCR2* and *CXCR1* antagonist with IC₅₀ values of 1.3 nM and 7.3 nM and K_i values of 1 nM and 3 nM, respectively ^[1] .

HY-125567

Antileukinate	CXCR	Inflammation/Immunology
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury ^[1] .

HY-10198R

Navarixin (Standard) SCH 527123 (Standard); MK-7123 (Standard)	Reference Standards CXCR	Inflammation/Immunology Endocrinology Cancer
Navarixin (Standard) is the analytical standard of Navarixin (HY-10198). This product is intended for research and analytical applications. Navarixin (SCH 527123) is a potent, allosteric and orally active antagonist of both CXCR1 and CXCR2, with K_d values of 41 nM for cynomolgus CXCR1 and 0.20 nM, 0.20 nM, 0.08 nM for mouse, rat and cynomolgus monkey CXCR2, respectivelly ^[1] .

HY-124183

SX-576	CXCR	Inflammation/Immunology
SX-576 is a *CXCR1* and *CXCR2* antagonist with IC₅₀ values of 31 nM and 21 nM, respectively. SX-576 inhibits neutrophil infiltration in a rat model of pulmonary inflammation. SX-576 can be used in studies related to pulmonary inflammation ^[1].

HY-10011R

SCH 563705 (Standard)	CXCR Reference Standards	Inflammation/Immunology Endocrinology
SCH 563705 (Standard) is the analytical standard of SCH 563705 (HY-10011). This product is intended for research and analytical applications. SCH 563705 is a potent and orally available CXCR2 and CXCR1 antagonist, with IC50s of 1.3 nM, 7.3 nM and Kis of 1 and 3 nM, respectively.

HY-15251AR

(Rac)-Reparixin (Standard) (Rac)-Repertaxin (Standard); (Rac)-DF 1681Y (Standard)	CXCR Reference Standards	Inflammation/Immunology Endocrinology Cancer
(Rac)-Reparixin (Standard) is the analytical standard of (Rac)-Reparixin. This product is intended for research and analytical applications. (Rac)-Reparixin is the isomer of Reparixin (HY-15251), and can be used as an experimental control. Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.

HY-P992035

AMY109	Interleukin Related	Endocrinology
AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with a K_a of 36.8 pM for human IL-8, and a K_a of 380 pM for cynomolgus monkey IL-8. AMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of *CXCR1* and *CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein*-1 production by neutrophils. AMY109 is applicable to research related to endometriosis ^[1].

HY-10011BR

(Rac)-SCH 563705 (Standard)	CXCR Reference Standards	Inflammation/Immunology Endocrinology
(Rac)-SCH 563705 (Standard) is the analytical standard of (Rac)-SCH 563705 (HY-10011B). This product is intended for research and analytical applications. (Rac)-SCH 563705 is a racemic mixture of SCH 563705 (HY-10011). SCH 563705 (compound 16) is a potent and orally active CXCR2 and CXCR1 antagonist with IC50 values of 1.3 nM and 7.3 nM and Ki values of 1 nM and 3 nM, respectively ^[1] .

Cat. No.	Product Name	Target	Research Area